EP2231132A2

EP2231132A2 - Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof

Info

Publication number: EP2231132A2
Application number: EP08872219A
Authority: EP
Inventors: Philippe Barthelemy; Michel Camplo; Nathalie Campins; Bruno Chauffert; Florence Bouyer
Original assignee: Universite Victor Segalen Bordeaux 2; Universite de la Mediterranee; Universite de la Mediterranee Aix Marseille II; Universite de Bourgogne
Current assignee: Aix Marseille Universite; Universite Victor Segalen Bordeaux 2; Universite de la Mediterranee; Universite de Bourgogne
Priority date: 2007-11-30
Filing date: 2008-11-28
Publication date: 2010-09-29
Also published as: US9533049B2; FR2924430A1; CN101932310A; WO2009098404A2; US20140308343A1; FR2924430B1; JP2015044815A; CA2706812A1; JP2017014243A; WO2009098404A8; US20110059180A1; JP5719594B2; JP2011504920A; JP6280167B2; CN101932310B; WO2009098404A3

Abstract

The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorisation of therapeutic agents, especially anti-tumoral agents.

Description

Process for the preparation of functional nanoparticles based on molecules or functional amphiphilic macromolecules and their use

The invention relates to a process for preparing nanoparticles based on functional amphiphilic molecules or macromolecules and their use for the transport or vectorization of therapeutic agents, in particular antitumor agents.

Among the anti-tumor agents, cis-platinum is a widely used antitumor agent, especially for the treatment of solid tumors. However, its use is limited by its toxicity and the appearance of acquired resistance.

To overcome these drawbacks, various formulations have been proposed in the prior art: for example, US Pat. No. 5,178,876 describes platinum derivatives in the form of a hydrophobic complex intended for encapsulation in liposomes.

US Pat. No. 6,001,817 describes compositions containing cisplatin and a vector comprising at least one nucleoside or deoxynucleoside.

US Pat. No. 7,908,160 relates to ligand-bound cis-platinum derivatives whose activity is reversible as a function of ligand binding.

Application WO01 / 32139 describes cis-platinum compositions encapsulated in lipophilic nanoparticles obtained by repeated cycles of heating and freezing, based on negatively charged natural lipids, in particular dioleylphosphatidylserine. It is stated in this application that cis-platinum forms positively charged aggregates in water with a higher solubility than uncharged species, allowing their interaction with negatively charged lipid membranes and reorganization of membranes. lipids around cis-platinum aggregates.

However, there is still a need to solve the problems associated with the vectorization of therapeutic agents, in particular anti-tumor agents. In particular, it is sought a means of allowing a transport of therapeutic agents (including cis-platinum and / or its derivatives) rapidly inside the tumor cells with a high pharmacological activity, while preserving the healthy cells is that is to say by decreasing the neurological, renal, auditory, digestive and other toxicity, while simultaneously limiting the phenomena of appearance of resistance to this therapeutic agent.

It is also sought to provide a vector having a stability in time sufficient to avoid the early release of the therapeutic agent and the disadvantages related to the presence of the free therapeutic agent in the biological medium, particularly in terms of loss of activity and toxicity.

It has now been found that the use of nanoparticles formed from functional amphiphilic molecules or macromolecules allows efficient and rapid intracellular delivery of therapeutic agents and has improved stability properties, particularly at 37 ° C, allowing prolonged vectorization in the time of said therapeutic agents.

By "therapeutic agents" is meant, for example, a natural or synthetic molecule used for the prevention or treatment of a pathology or the restoration of a biological function, in vitro or in vivo, in particular in animals, including humans, or isolated cells, with the exception of nucleic acids or their fragments.

Such a molecule may be chosen, for example, from the active ingredients of medicaments, in particular from anti-tumor agents such as, for example:

platinum complexes, among which we may especially mention cis-platinum, carboplatin, oxaliplatin, nedaplatin, lobaplatin, etc., or ruthenium capable of binding to platinum complexes, or platinum-free inorganic complexes based on ruthenium II and / or III, titanium, for example titanocene or gallium dichloride, for example gallium salts such as gallium nitrate, gallium chloride, KP46 or iron derivatives, such as, for example, ferrocenium salts, iron-containing nucleoside analogues, iron (II) complexes containing pyridyl pentadenate ligands, or

cobalt derivatives, such as, for example, hexacarbonyl-dicobalt complexes, alkyne-cobalt complexes, the Co (III) complex containing a bicyclic nitrogen ligand, or

gold derivatives such as, for example, Auranofin, gold complexes (I), (III) and (III), aurothioglucose, etc.

Advantageously, the use of nanoparticles formed from functional amphiphilic molecules or macromolecules of formula (I) for encapsulating these compounds and ensuring their intracellular delivery makes it possible to limit the phenomena of resistance to these compounds.

Platinum complexes, in particular cis-platinum, are preferred therapeutic agents for the purpose of the invention.

Inorganic complexes based on ruthenium II and / or III may be, for example, the complexes called NAMI-A, RAPTA-C, KP1019. Such non-platinum complexes are described in Ott I. and Gust R., Arch. Pharm. Chem. Life ScL 2007, 340, 117-126; Reedijk J., Curr Opin Chem Biol., 1999, 3, 236-40; Haimei Chen et al., J. Am. Chem. Soc., 2003, 125, 173-186. Iron-containing nucleoside analogues are described in US Pat.

Schlawe D. et al, Angew. Chem. Int. Ed., 2004, 1731-1734.

The invention thus relates, in a first aspect, to a method of encapsulating a therapeutic agent, preferably an antitumor agent, comprising the steps of: a) preparing a mixture of at least one functional amphiphilic compound of formula (I) in which

X represents an oxygen atom, sulfur atom or a methylene group; - B represents a purine or pyrimidine base such as uracil, adenine, guanine, cytosine, thymine, hypoxanthine, or their derivatives, or a mono- or bi heterocyclic base; non-natural cyclic of which each cycle has 4 to 7 members, optionally substituted; I 1 and L ₂ , which may be identical or different, represent hydrogen, an oxycarbonyl group -O-C (O) -, a thiocarbamate group -O-C (S) -NH-, a carbonate group -O-C (O) -O-, a carbamate group -O-C (O) -NH-, an oxygen atom, a phosphate group, a phosphonate group or a heteroaryl group comprising 1 to 4 nitrogen atoms, substituted or unsubstituted by a hydrocarbon chain, saturated or unsaturated, linear or branched C ₂ - C ₃₀ , or, Li and L ₂ together form a ketal group of formula

or alternatively Li or L ₂ represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched C ₂ -C _{3 0} alkyl _chain;

Ri and R ₂ , identical or different, represent

- a linear or branched hydrocarbon chain C ₂ -C _30, preferably Ce-C _25, particularly C ₈ -C ₂₅ saturated or partially unsaturated, optionally partially or completely fluorinated, unsubstituted or substituted on the atoms of chain end with a fluorine atom or with a benzyl or naphthyl ester or ether, or a diacyl chain in which each C ₂ -C ₃ ₀ acyl chain, or

a diacylglycerol, sphingosine or ceramide group, or

when Li or L ₂ represents hydrogen and the other represents a hydroxyl group or a heteroaryl group comprising 1 to 4 nitrogen atoms, R 1 and R 2 do not exist;

R ₃ represents

a hydroxy, amino, phosphate, phosphonate, phosphatidylcholine, O-alkylphosphatidylcholine, thiophosphate, phosphonium, NH ₂ -R ₄ , NHR ₄ R ₅ or NR ₄ R ₅ Re group in which R ₄ , R ₅ and R ₆ , which are identical, or different, represent a hydrogen atom or a linear or branched alkyl chain-C ₅ linear or branched hydroxyalkyl, or Cr _C5, or

a linear or branched C ₂ -C ₃₀ alkyl chain optionally substituted by a hydroxyl group, or a cyclodextrin residue, or

- a remainder

R ₇

I

H - (- CH ₂ -O) _n -HI

CO-V- wherein V is -O -, - S-, or -NH-, R ₇ is H or

CH ₃ , and n = 1 to 500, or a - (CH ₂ ) _n -V-R _{8 group,} wherein R ₈ is C ₂ -C ₃ O alkyl, and n = 1 to 500, or

- a heteroaryl group containing 1-4 nitrogen atoms, unsubstituted or substituted with a C ₂ -C _3O, or a group (CH ₂₎ _m -O- (CH2) p-R9 wherein m = 1 at 6 and p = 0 to 10 and Rg represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C ₂ -C ₃₀ alkyl or by a sterol residue, or

- R ₃ is covalently linked to another substituent R ₃ , identical or different, of another compound of formula (I), identical or different, to form a compound of formula (I) in the form of a dimer, and a therapeutic agent, preferably an anti-tumor agent,

b) subjecting said mixture to repeated cycles of heating and freezing, so as to obtain nanoparticles containing said therapeutic agent, and c) recovering the nanoparticles containing said therapeutic agent thus obtained.

Advantageously, it has been found that the molecular and / or macromolecular structures which constitute the compounds of formula (I), comprising at least one ligand of the therapeutic agent (nucleobase, nucleoside, modified nucleoside, nucleotides, oligonucleotide, heterocycle, etc. ) represented by the substituent B, and having an amphiphilic character because of the presence of at least one hydrophilic part (phosphate, carboxylate, etc.), and at least one hydrophobic part (single-stranded hydrophobic segments, double-stranded and polar parts derived synthons of biological origin, etc.), made it possible to form stable nanoparticles with the therapeutic agent.

By the combination of the amphiphilic properties of the compounds of formula (I), the presence of ligands of the therapeutic agent (active principle) in these compounds and any electrostatic interactions between the therapeutic agents and these compounds, the nanoparticles thus obtained exhibit a structure allowing an efficient and rapid intracellular delivery of encapsulated active ingredients, in particular anti-tumor agents. Without wishing to link the invention to a theory, it can be hypothesized that the intermolecular interactions of the compounds of formula (I) induce an increase in the cohesion forces on the surface of the nanoparticles, which results in greater stability in time, under the conditions of use. Advantageously, said nanoparticles also have a shelf life compatible with their use as a therapeutic agent vector. In the formula (I) above, n is advantageously between 1 and 500, preferably between 1 and 100, in particular between 1 and 50, most particularly between 1 and 10.

By "linear or branched C ₁ -C ₅ alkyl" is meant for example a methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl or tert-butyl radical, preferably methyl or ethyl.

Also, in formula (I) above, the purine or pyrimidine base, or the non-natural heterocyclic base may be substituted with at least one substituent selected from, for example, a halogen, an amino group, a carboxy group, a carbonyl group, carbonylamino group, hydroxy, azido, cyano, alkyl, cycloalkyl, perfluoroalkyl, alkyloxy (for example, methoxy), oxycarbonyl, vinyl, ethynyl, propynyl, acyl and so on.

The term "non-natural heterocyclic base" means a base other than uracil, adenine, guanine, cytosine, thymine or hypoxanthine, which does not exist in nature.

By "heteroaryl group containing 1 to 4 nitrogen atoms" is meant a monocyclic or bycyclic carbocyclic group, aromatic or partially unsaturated, containing 5 to 12 atoms, interrupted by 1 to 4 nitrogen atoms, in particular the pyrazole groups, triazole, tetrazole or imidazole.

For the preparation of the compounds of formula (I), reference can be made to the application WO 2005/116043, which describes different routes of access to this type of compound (see in particular pp. 8-17 and examples).

The method according to the invention may comprise the steps implemented in the following general conditions:

the compound of formula (I) is dissolved in an organic solvent to form a lipidic mixture and then, after removal, evaporated to form a film;

in parallel, the desired quantity of therapeutic agent, preferably an anti-tumor agent, is dissolved in distilled water; the lipid film is rehydrated in the therapeutic agent solution, preferably an anti-tumor agent. A clear solution is obtained by sonification and heating;

the solution is rapidly cooled, for example by immersion in liquid nitrogen. This heating / cooling cycle is preferably carried out from 1 to 10 times, in particular from 5 to 10 times, in particular 10 times.

The solution obtained is centrifuged. The supernatant is discarded. After several centrifugations, the pellet is dried.

The organic solvent may be chosen, for example, from organic solvents customary in the field, such as, for example, chloroform, an alcohol such as methanol or ethanol, etc.

The heating is preferably carried out at a temperature of the order of 20 ^° C. to 80 ^° C. and the cooling at a temperature of the order of

190 ° C (liquid nitrogen) at 0 ^° C (ice). A suitable heating / cooling cycle may, for example, be 45 ° C for heating and -78 ° C for cooling.

Preferably, the therapeutic agent is chosen from platinum complexes (cis-platinum, carboplatin, etc.), cis-platinum being particularly preferred, or ruthenium capable of binding to platinum complexes, or else platinum-free inorganic complexes based on ruthenium II or III, titanium, gallium, cobalt, iron or gold mentioned above.

The molar ratio R of the compound of formula (I) / therapeutic agent may be, for example, between 0.01 to 50, in particular R = 0.2.

The nanoparticles obtained may optionally be extruded on a polycarbonate filter having, for example, a pore diameter of the order of 100 or 200 nm.

Solid nanoparticles are thus obtained which consist of a core rich in therapeutic agent (active principle) surrounded by one or more lipid layers consisting of functional amphiphilic compound of formula (I) as defined above, with or without co-lipid . Said nanoparticles, solid, consisting of a core rich in therapeutic agent, preferably an antitumor agent, in particular a platinum complex, surrounded by one or more lipid layers consisting of functional amphiphilic compound of formula (I) as defined above , with or without co-lipid, represent a further object of the invention.

In the case of a multi-layer surround, all the lipid layers consist of the same lipids (compound of formula (I) with or without co-lipid).

According to one aspect of the invention, it will be used in the lipid mixture, in addition to the compound of formula (I), at least one colipid.

By "colipid" is meant a compound used in combination with the compound of formula (I), which participates in the development of the structure of the lipid layer (s) of the nanoparticle.

A zwitterionic colipid will preferably be used. Said colipid may be, for example, chosen from dioleylphosphatidylcholine (DOPC) or dioleylphosphatidyluridine phosphatidylcholine (DOUPC), in combination with the compound of formula (I) to form the lipid layer (s) of the nanoparticle.

These compounds can act as colipids when used in admixture with a compound of formula (I). Alternatively, they can be included in formula (I), such as, for example, dioleylphosphatidyluridinephosphatidylcholine (SOHC). In this case, they will play either the role of compound of formula (I) or, in combination with another compound of formula (I), the role of colipid. According to a preferred aspect of the process, said lipid mixture contains only at least one compound of formula (I) and does not contain a colipid.

The therapeutic agent will preferably be used at a concentration of the order of 0.1 ng / ml to 10 mg / ml in the aqueous phase, so that the intracellular delivery of the active principle is important.

Preferred compounds of formula (I) are those wherein X is oxygen. The compounds of formula (I) in which B represents thymine or adenine are also preferred compounds.

Among the compounds of formula (I) which are particularly advantageous for the purposes of the invention, mention may be made of the compounds of formula (I) in which: X and B are as defined above;

L 1 represents a phosphate group, L ₂ represents hydrogen, R 1 represents a C ₂ -C ₃₀ alkyl group or a diacyl group in which each acyl chain is C ₂ -C 3 _O , and R ₃ is a hydroxyl group; or

Li and L ₂ represent an oxygen atom, R ₁ and R ₂ represent hydrogen and R ₃ represents a triazole group, tetrazole, pyrazole or imidazole substituted with a C ₂ -C ₃₀ alkyl group, or

Li represents a triazole, tetrazole, pyrazole or imidazole group, L ₂ represents hydrogen, R ₁ represents a C ₂ -C ₃₀ alkyl group and R _{3 represents} a hydroxy group, or - Li represents a hydroxyl group, L ₂ represents hydrogen and R ₃ is a triazole group substituted by a C ₂ -C ₃₀ alkyl chain, optionally substituted by a hydroxy group, or R ₃ is a group or a - (CH ₂ ) n - VR _{8 group} , in wherein V is -O- or -NH- and R ₈ is C ₂ -C ₃₀ alkyl, or - Li is hydroxy, L ₂ is hydrogen, and R ₃ is triazole substituted with (CH) ₂₎ _{ι π-O-} (CH ₂₎ _p -Rg wherein m = 1 to 6 and p = 0 to 10 and R ₉ represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted with at least a linear or branched C ₂ -C ₃₀ alkyl group or a sterol residue, or - Li represents a hydroxyl group, L ₂ represents hydrogen and R ₃ is a triazol group e substituted by a group (CH2) _m ~ O- (CH ₂ ) _p -R9 in which m = 1 to 6 and p = 0 to 10 linked by covalent bond to another substituent R ₃ , identical, of another compound of formula (I), identical, to form a compound of formula (I) in the form of a dimer, or - L ₁ represents a phosphate group, L ₂ represents hydrogen R ₁ represents a diacyl chain in which each diacyl chain is in C ₂ -C ₃₀ , and R ₃ is a hydroxy group, which are new compounds.

The compounds of formula (I) in which the Li substituent or the substituent R 3 is composed of or comprises an unsubstituted or substituted triazole group, are also new preferred compounds for the purposes of the process according to the invention.

The above compounds are novel compounds which represent an object of the invention, as well as the nanoparticles comprising these compounds and a therapeutic agent, in particular an anti-tumor agent, in particular platinum complexes (such as, for example cis-platinum, carboplatin, oxaliplatin, nedaplatin, lobaplatin,), or ruthenium capable of binding to platinum complexes, or inorganic complexes without platinum based on ruthenium, titanium, gallium , cobalt, iron or gold mentioned above. Cisplatin is a preferred anti-tumor agent for the purpose of the invention. The compounds of formula (I) may comprise purine or pyrimidine base derivatives having antineoplastic activity, such as, for example, aracytosine (AraC), 5-fluorouracil (5-FU), lododeoxyuridine (IdU) 2'-deoxy-2'-methylidenecytidine (DMDC) or 5-chloro-6-azido-5,6-dihydro-2'-deoxyuridine.

The invention also relates to the use of nanoparticles that can be obtained by the method described above, for the transport or vectorization of therapeutic agents, in particular antitumor agents. In particular, the invention relates to the use of the nanoparticles that can be obtained by the method described above, for the intracellular delivery of therapeutic agents, in particular antitumor agents.

The invention also relates to the use of the nanoparticles that can be obtained by the above process, for the preparation of anti-tumor drugs.

The invention also relates to the nanoparticles that can be obtained by the above process, for the treatment of diseases tumors, particularly cancers, such as, for example, ovarian, testicular, colon, cervical, lung, or adenosarcoma etc.

The invention is illustrated in a nonlimiting manner by the examples below.

All of the starting materials come from chemical suppliers (Aldrich, Alfa Aesar and Avanti Polar Lipid) and are used without further purification. The solvents were used without further distillation. The synthesized compounds were characterized using standard spectroscopic analytical methods such as ¹ H NMR at 300.13 MHz, ¹³ C at 75.46 MHz and ³¹ P at 121, 49 MHz) and mass spectroscopy (Features ). The chemical shifts (δ) in NMR are expressed in ppm and relative to the TMS. The ¹ H NMR coupling constants are expressed in Hz. Merck RP-18 F254s plates were used for thin layer chromatography (TLC). SEPHADEX LH-20 silica (25-100 μm) was used for purifications by quantitative chromatography.

The examples below, entitled "Preparation" describe the preparation of synthetic intermediates used to prepare the compounds of formula (I). The preparation of the compounds of formula (I) is described next in the synthesis examples entitled "Example".

Preparation 1

5'-Paratoluenesulfonylthymidine

In a two-neck flask under an anhydrous nitrogen atmosphere, 2 g of thymidine (8.26 mmol) in 0.1 M solution in anhydrous pyridine are introduced. The solution is then cooled to 0 ^° C. and 3.935 g of para-toluenesulphonic acid chloride (2.5 equivalents, 20.6 mmol) are added in small portions. The reaction medium is allowed to return to ambient temperature and then stirred for 10 hours. The reaction is then stopped by adding 10 mL of methanol, stirring is maintained for 30 min. 50 ml of CH ₂ Cl ₂ are added to the mixture and then washed successively with 20 ml of a 5% solution of NaHCO ₃ , 20 ml of a saturated solution of NaCl and 20 ml of a 5% solution of NaHCO 3. ₃ . The solvent is removed under reduced pressure. The expected compound is obtained pure by recrystallization from methanol.

RF: 0.47 (AcOEt / MeOH 9/1)

Yield: 75%

¹ H NMR (300.13 MHz, DMSO d ₆ ): δ 1.77 (s, 3H, CH ₃ ), δ 2.11 (m,

2H, CH ₂ ), δ 2.42 (s, 3H, CH ₃ ), δ 3.52 (t, y = 6 Hz, 4H, CH ₂ ), δ 4.18 (m, 1H, CH), δ 4.25 (m, 3H, CH, CH ₂ ), δ 5.42 (s, 1H, OH), δ 6.15 (t, j = 6 Hz, H, CH), δ 7.38 (s, 1H ₁ CH), δ 7.46 (s, 1H, CH), δ 7.49 (s, 1H, CH), δ 7.78 (s, 1H, CH), δ 7.81 ( s, 1H, CH), δ 11, 28 (s, 1 H ₁ NH). ¹³ C NMR (75.47 MHz, DMSO d _β ): δ 12.5 (CH ₃ ), δ 21, 6 (CH ₃ ), δ

38.9 (CH ₂ ), δ 70.4 (CH ₂ ), δ 70.6 (CH), δ 83.7 (CH), δ 84.5 (CH), δ 110.3 (C), δ 128.1 (CH ar), δ 130.6 (2 CH ar), δ 132.6 (C ar), δ 136.4 (C ar), δ 145.6 (C), δ 150.8 (C = O), δ 164.1 (C = O).

SM High [M + H] ⁺ : 397.1

Preparation 2 2'-Deoxy-5'-toluenesulfonyladenosine

In a two-neck flask under an anhydrous nitrogen atmosphere, 2 g of 2'-deoxyadenosine (8 mmol) in 0.1 M solution in anhydrous pyridine are introduced. The solution is then cooled to 0 ^° C. and 3.793 g of para-toluenesulphonic acid chloride (2.5 equivalents, 20 mmol) are added in small portions. The reaction medium is allowed to return to ambient temperature and then stirred for 10 hours. The reaction is then stopped by adding 10 mL of methanol, stirring is maintained for 30 min. 50 ml of CH ₂ Cl ₂ are added to the mixture and then washed successively with 20 ml of a 5% solution of NaHCO ₃ , 20 ml of a saturated solution of NaCl and 20 ml of a 5% solution of NaHCO _3. ₃ . The solvent is removed under reduced pressure. The expected compound is obtained pure by recrystallization from methanol. 2.1 g of a white product are thus isolated.

RF: 0.37 (AcOEt / MeOH 9/1)

Yield: 63%

Preparation 5'-5'-azido-deoxythymidine

In a two-neck flask equipped with a condenser and under an anhydrous nitrogen atmosphere, 2 g of 5'-para-toluenesulfonylthymidine (5 mmol) as described in Preparation 1 in 0.1M solution in DMF are introduced. 1.3 g of sodium azide (4 equivalents, 20 mmol) are added. The solution is then stirred and heated at 110 ^° C. for 10 h. The mixture is cooled to room temperature. 50 ml of CH ₂ Cl _{2 are} added to the mixture and then washed successively with twice 15 ml of water and then with 15 ml of a saturated aqueous solution of NaCl.

The organic phase is dried over sodium sulfate and the solvent is removed under reduced pressure. The expected compound is obtained pure by recrystallization from methanol. 0.8 g of a white solid are thus obtained.

RF: 0.47 (AcOEt / MeOH 9/1)

Yield: 60%

MS [M + H] ⁺ : 268.1

Preparation 4

5'-azido-5 ', 2'-dideoxyadenosine

2 g of 2'-deoxy-5'-para-toluenesulfonyladenosine as described in Preparation 2 (5 mmol) in 0.1 M solution are introduced into a two-neck flask equipped with a condenser and under an anhydrous nitrogen atmosphere. in the DMF.

1.3 g of sodium azide (4 equivalents, 20 mmol) are added. The solution is then stirred and heated at 110 ^° C. for 10 h. The mixture is cooled to room temperature. 50 ml of CH ₂ Cb are added to the mixture and then washed successively with twice 15 ml of water and then with 15 ml of a saturated aqueous solution of NaCl. The organic phase is dried over sodium sulphate and then solvent is removed under reduced pressure. The expected compound is obtained pure by recrystallization from methanol. 0.8 g of a white solid are thus obtained.

RF: 0.37 (AcOEt / MeOH 9/1)

Yield: 60% MS High resolution [M + H] ⁺ : calculated mass: 277.1161, measured mass: 277.1157

Preparation 5 1-propargyloxyoctadecane

In a clean and dry flask, under an anhydrous nitrogen atmosphere, are introduced 673 mg of propargyl alcohol (12 mmol) in 0.5M solution in DMF. The solution is then cooled to 0 ^° C. and 180 mg of sodium hydride (0.625 equivalents, 7.5 mmol) are added in small portions. The reaction medium is allowed to return to room temperature. 2 g of 1-bromoocadecane (0.5 equivalents, 6 mmol) are added. Stirring is maintained for 5 hours. The reaction is then stopped by adding 10 mL of methanol and the stirring is maintained for 30 min. 50 ml of CH ₂ Cl ₂ are added to the mixture and then washed successively with twice 20 ml and 20 ml of a saturated solution of NaCl. The organic phase is then dried over Na ₂ SO ₄ and the solvent is removed under reduced pressure. The expected compound is obtained pure after separation on a chromatographic column (hexane). 1.2 g of a white product are thus isolated.

RF: 0.82 (Hexane) Yield: 65%

¹ H NMR (300.13 MHz, CDCl ₃ ): δ 0.90 (t, j = 6 Hz, 3H, CH ₃ ), δ

1, 28 (s, 3OH, CH ₂ ), δ 1, 61 (m, 2H, CH ₂ ), δ 2.43 (t, / = 3 Hz, 1H, CH 2), δ 3.53 (t, y = 6 Hz, 2H, CH ₂ ), δ 4.15 (d, y = 3 Hz, 2H, CH ₂ ). ¹³ C NMR (75.47 MHz, CDCl ₃ ): ¹³ C NMR (75.47 MHz, CDCl ₃ ): δ 14.2 (CH ₂ ), δ 22.7 (CH ₂ ), δ 26.1 (CH ₂ ), δ 29.4 (CH ₂ ), δ 29.5 (CH ₂ ), δ 29.6 (CH ₂ ), δ 32.0 (CH ₂ ), δ 58.0 (CH ₂ ), δ 70 , 4 (CH ₂ ), δ 74.1 (CH), δ 80.1 (C).

Preparation 6

1,2-propargyloxydodecane 12-propargyloxydodecan-1-ol

In a clean and dry flask, under an anhydrous nitrogen atmosphere, 1 g of dodecan-1,2-diol (5 mmol) in 0.5M solution in DMF is introduced.

The solution is then cooled to 0 ^° C. and 360 mg of hydrogen hydride (3 equivalents, 15 mmol) are added in small portions. The reaction medium is allowed to return to room temperature. 1.49 g of propargyl bromide

(2.5 equivalents, 12.5 mmol) are added. Stirring is maintained for 5 hours. The reaction is then stopped by adding 10 mL of methanol, stirring is maintained for 30 min. 50 ml of CH ₂ Cl ₂ are added to the mixture and then washed successively with twice 20 ml and 20 ml of a saturated solution of NaCl.

The organic phase is then dried over Na ₂ SO ₄ and the solvent is removed under reduced pressure. The products obtained are then separated on a chromatographic column (Hex / ActEth 9/1). Two products are isolated, namely

370 mg of a brown oil corresponding to 1, 12-Propargyloxydodecane and 430 mg of a brown solid corresponding to 12-propargyloxydodecan-1-ol.

1, 12-propargyloxydodecane

RF: 0.53 (Hexane / AcOtEt 9/1)

Yield: 27%

¹ H NMR (300.13 MHz, CDCl ₃ ): δ 1, 31 (m, 16H, CH ₂ ), δ 1, 61 (m, 4H, CH ₂ ), δ 2.43 (t, y = 3 Hz , 1H, CH), δ 3.52 (t, y = 6 Hz, 4H, CH ₂ ), δ 4.15 (d, = 3 Hz, 4H, CH ₂ ). ¹³ C NMR (75.47 MHz, CDCl ₃ ): δ 26.1 (CH ₂ ), δ 29.4 (CH ₂ ), δ 29.5 (CH ₂ ), δ 29.6 (CH ₂ ), δ 58.0 (CH ₂ ), δ 70.3 (CH ₂ ), δ 74.1 (CH), δ 80.1 (C).

12-propargyloxydodecan-1-ol

RF: 0.10 (Hexane / AcOtEt 9/1)

Yield: 36%

¹ H NMR (300.13 MHz, CDCl ₃ ): δ 1, 32 (m, 16H, CH ₂ ), δ 1, 59 (m, 4H ₁ CH ₂ ), δ 2.43 (t, j = 3 Hz , 2H, CH), δ 3.52 (t, j = 6 Hz, 2H, CH ₂ ), δ 3.65 (t, j = 6 Hz, 2H, CH ₂ ), δ 4.15 (d, y ^" = 3 Hz, 2H, CH ₂ ).

¹³ C NMR (75.47 MHz, CDCl ₃ ): δ 25.8 (CH ₂ ), δ 26.0 (CH ₂ ), δ 29.4 (2 CH ₂ ), δ 29.5 (2 CH ₂ ) , δ 29.6 (CH ₂ ), δ 32.7 (CH ₂ ), δ 57.9 (CH ₂ ), δ 62.7 (CH ₂ ), δ 70.2 (CH ₂ ), δ 74.2 (CH), δ 79.9 (C).

Preparation 7 o-propargylcholesterol

In a clean and dry flask, under an anhydrous nitrogen atmosphere, 500 mg of cholesterol (1.3 mmol) in 0.5 M solution in DMF are introduced. The solution is then cooled to 0 ^° C. and 47 mg of sodium hydride (1.5 equivalents, 2 mmol) are added in small portions. The reaction medium is allowed to return to room temperature. 238 mg of propargyl bromide (1.5 equivalents, 2 mmol) are added. Stirring is maintained for 5 hours. The reaction is then stopped by adding 10 mL of methanol and the stirring is maintained for 30 min. We add to the mixture 50 ml of CH ₂ Cl ₂ and then washed successively with 2 times 20 ml and 20 ml of saturated NaCl solution. The organic phase is then dried over Na ₂ SO ₄ and the solvent is removed under reduced pressure. The expected compound is obtained after purification on a chromatographic column (Hexane / AcOEt 8/2). 215 mg of a white product are thus isolated.

RF: 0.83 (Hexane / AcOEt 8/2) Yield: 39%

Example 1

Thymidine 3 '- (1,2-dimyristoyl-sn-glycero-3-phosphate) (diC14dT)

5'-O- (4,4'-dimethoxytrityl) -2'-deoxythymidine, 3 '- [(2-cyanoethyl) -N, N-diisopropyl)] phosphoramidite (0.500 g, 1 eq, 0, 67 mmol), 1,2-dimyristoyl-sπ-glycerol (0.447 g, 1.3 eq, 0.87 mmol) and a solution of 0.45 M tetrazole in acetonitrile (2 mL, 1.3 eq. 0.87 mmol) are dissolved in 4 mL of anhydrous acetonitrile under nitrogen. The reaction medium is stirred magnetically for 24 hours at room temperature. The mixture is then oxidized by adding 43 ml of a solution of 0.02M diiod in THF / Pyr / H ₂ O. After 12 h at room temperature, the solvent is evaporated in vacuo. The residue is dissolved in 8 mL of dichloromethane. Then 0.2 mL of 1, 5- diazabicyclo [5.4.0] undec-7-ene (DBU) (1.3 eq, 0.87 mmol) are added to the reaction medium for 5 h. The reaction medium is washed with a 0.1N solution of HCl and then with a saturated solution of Na ₂ S ₂ O ₇ . The organic phase is concentrated under vacuum. The compound is obtained after purification by flash chromatography (381 mg) using an elution gradient (MeOH / DCM 9: 1 to 1: 1).

Yield: 69%

Rf: 0.34 (DCM / MeOH 9: 1)

1 H NMR (300 MHz, CDCl 3): δ in ppm 0.84 (t, 6H, J = 6.92 Hz,

2 * CH ₃ ), 1, 21 (m, 4OH, 20 * CH ₂ ), 1, 42 (dd, 4H, J1 = 8.45 Hz, J2 = 15.68 Hz, 2 * CH2), 1.89 (s, 3H, Me), 2.30 (dd, 4H, J1 = 7.43 Hz, J2 = 15.92 Hz, 2 * CH2), 2.83 (t, 2H, J = 5.84, H2 '), 3.84 (m, 1H, H3') _f 4.09 to 4.35 (m, 7H, 2 * CH ₂ (glycerol), H4 ', H5'), 5.27 (s, 1H , Glycerol), 6.22 (t, 1H, J = 6.81 Hz, HT), 7.61 (s, 1H, Hbase).

13 C NMR (75 MHz, CDCl 3): δ in ppm 19.29 (CH ₃ ), 23.71 (CH ₂ ), 26.57 (CH ₂ ), 28.73 (CH ₂ ), 32.76 (CH ₂₎ ), 37.85 (CH ₂ ), 48.90 (CH ₂ ), 166.15 (C = O).

31 P NMR (121 MHz, CDCl3): δ in ppm 0.61.

High Resolution mass FAB- theoretical m / z = 815.4823 observed m / z = 815.4794.

Example 2

Thymidine 3 '- (1, 2-dipalmitoyl-sn-glycero-3-phosphate) (di C16dT)

5'-O- (4,4'-dimethoxytrityl) -2'-deoxythymidine, 3 '- [(2-cyanoethyl) -N, N-diisopropyl)] phosphoramidite (0.500 g, 1 eq, 0, 67 mmol), 1,2-dipalmitoyl-sn-glycerol (0.496 g, 1.3 eq, 0.87 mmol / solubilized in 3 ml of THF) and a solution of 0.45 M tetrazole in acetonitrile (2 g). mL, 1.3 eq, 0.87 mmol) are dissolved in 3 mL of anhydrous acetonitrile under nitrogen. The reaction medium is stirred magnetically for 24 hours at room temperature and under nitrogen. The mixture is then oxidized by adding 43 ml of a solution of 0.02M diiodode in THF / Pyr / H ₂ O. After 12 h at room temperature, the solvent is evaporated under vacuum and dried at the pump under P ₂ O ₅ overnight. The residue is dissolved in 8 mL of dichloromethane. Then, 0.2 ml of 1,5-diazabicyclo [5.4.0] undec-7-ene (DBU) (1.3 eq, 0.87 mmol) are added to the reaction medium for 5 h. The reaction medium is washed with a solution of 0.1N HCl and then with a saturated solution of Na ₂ S ₂ O ₃ . The organic phase is concentrated under vacuum. The compound is obtained after purification by flash chromatography (180 mg) using an elution gradient (MeOH / DCM 98: 2 to 1: 1). Yield: 24% Rf: 0.3 (DCM / MeOH 8: 2)

1 H NMR (300 MHz, CDCl 3): δ in ppm 0.88 (t, 6H, J = 6.9 Hz, 2 * CH ₃ ), 1.25 (m, 48H, 24 * CH ₂ ), 1.42 (dd, 4H ₁ J1 = 8.4 Hz, J2 = 15.6 Hz, 2 * CH2), 1.90 (s, 3H, Me), 2.33 (m, 4H, 2 ^* CH ₂ ), 2.83 (t, 2H, J = 5.6 Hz, H ₂ '), 3.84 (m , 1H, H3 '), 4.09-4.35 (m, 7H, 2 ^* CH ₂ (glycerol), H ₄ ¹ , H ₅ '), 5.27 (s, 1H, CH glycerol), 6.21 (t, 1H, J = 6.7 Hz, Hf), 7.54 (s, 1H, H base).

13 C NMR (75 MHz, CDCl 3): δ in ppm 12.4 (CH ₃ base), 14.1 (CH ₃ chain), 19.6 (CH ₂ ), 19.7 (CH ₂ ), 22.6 ( CH _2), 24.8 (CH _2), 29.1 to 29.6 (CH _2), 31, 9 (CH _2), 33.9 (CH _2), 34.1 (CH ₂₎ 61, (CH ₂ ), 61.7 (CH ₂ ), 62.5 (CH ₂ ), 62.6 (CH ₂ ), 66.1 (CH ₂ ), 66.2 (CH ₂ ), 69.1 (CH ₂ ), CH), 78.8 (CH), 85.5 (CH), 86.1 (CH), 111.3 (C base), 136.8 (CH base), 150.5 (C = O base), 164.1 (C = O base), 173.0 (C = O chain), 173.5 (C = O chain).

31 P NMR (121 MHz, CDCl3): δ in ppm 2.1.

ESI mass: theoretical m / z = 872.5 observed m / z = 871.3.

Example 3

5 '- (4-Hexadecyloxymethyl-1,2,3-triazol-1-yl) -5', 2'-dideoxythymidine

200 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.75 mmol) and 231 mg of 1-propargyloxyoctadecane as described in Preparation 5 (1 equivalent) are introduced into a flask. 0.1 M solution in a mixture of THF and water (1/1). Then, successively, 30 mg of sodium ascorbate (0.2 equivalents, 0.15 mmol) and 12 mg of copper sulfate (0.1 equivalents, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. 180 mg of a white solid are obtained after chromatography on a silica column (AcOEt / MeOH 8/2). RF: 0.72 (AcOEt / MeOH 8/2)

Yield: 42%

MS High resolution [M + H] ⁺ : calculated mass: 576.4125, measured mass: 576.4120

Example 4

5 '- (4-Hexadecyloxymethyl- [1,2,3] triazol-1-yl) -5', 2'-dideoxyadenosine

200 mg of 5'-azido-5 ', 2'-dideoxyadenosine as described in Preparation 4 (0.72 mmol) and 223 mg of 1-propargyloxyoctadecane as described in Preparation 5 (1) are introduced into a flask. equivalent) in 0.1M solution in a mixture of THF and water (1/1). Then, successively, 30 mg of sodium ascorbate (0.2 equivalents, 0.15 mmol) and 12 mg of sulfate are added successively. copper (0.1 equivalent, 0.075 mmol). The reaction medium is stirred and heated at 60 ^° C. for 5 h, then the mixture is cooled to ambient temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. 150 mg of a white solid are obtained after column chromatography (AcOEt / MeOH 8/2).

RF: 0.65 (AcOEt / MeOH 8/2) Yield: 35%

¹ H NMR (300.13 MHz, CDCl ₃ ): δ 0.89 (t, y = 6 Hz, 3H ₁ CH ₃ ), δ 1, 26

(m, 3OH, CH ₂ ), δ 1, 55 (m, 2H, CH ₂ ), δ 2.54 (m, 1H, CH ₂ ), δ 3.06 (m, 1H, CH ₂ ), δ

3.45 (t, y = 6 Hz, 2H, CH ₂ ), δ 4.50 (m, 4H, CH ₂ , CH), δ 4.89 (m, ???), δ 5.88 (s , 2H ₁ NH ₂ ), δ 6.40 (t, j = 6Hz, 1H, CH), δ 7.42 (s, 1H, CH), δ 7.81 (s, 1H,

CH), δ 8.35 (s, 1H ₁ CH).

SM High resolution [M + H] ⁺ : calculated mass: 585.4241, measured mass: 585.4254

Example 5

5 '- (4- (1-hydroxyhexyl) - [1,2,3] triazol-1-yl) -5', 2'-dideoxythymidine

215 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.8 mmol) and 101 mg of the racemic mixture of oct-1-yn-3-ol (1 equivalent) are introduced into a flask. in 0.1M solution in a THF water mixture (1/1). 31.5 mg of sodium ascorbate (0.2 equivalent, 0.15 mmol) and 13 mg of copper sulfate (0.1 equivalent, 0.075 mmol) are then added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is then immediately adsorbed on silica and the solvent removed by evaporation. The compound is obtained pure by column chromatography (AcEt / MeOH 85/15). 255 mg of a white solid are obtained. RF: 0.48 (AcOEt / MeOH 85/15)

Yield: 78% ¹ H NMR (300.13 MHz, DMSO d ₆ ): δ 0.83 (t, j = 6 Hz, 3H, CH ₃ ), δ

1, 24 (m, 6H, CH ₂ ), δ 1, 68 (m, 2H, CH ₂ ), δ 1, 81 (s, 3H, CH ₃ ), δ 4.06 (m, 1H,

CH), δ 4.27 (m, 1H, CH), δ 4.62 (m, 3H, CH ₂ , CH), δ 5.2 (d, y = 6 Hz, 1H, OH), δ

5.5 (s, 1H ₁ OH), δ 6.17 (W = 6 Hz, 1H, CH), δ 7.37 (s, 1H, CH), δ 7.89 (s, 1H) , CH).

¹³ C NMR (75.47 MHz, DMSO d ₆ ): δ 12.5 (CH ₃ ), δ 014.4 (CH ₃ ), δ 22.6 (CH ₂ ), δ 25.1, δ 31, 7 (CH ₂ ), δ 38.4 (CH ₂ ), δ 51, 6 (CH ₂ -N), δ 66.0 (CH 2 O), δ 71, 3 (C), δ 84.4, δ 84 , 5, δ 110.3 (= CN), δ 122.8, δ 136.4, δ 150.9, δ 152.4, δ 164.1. MS High resolution [M + Na] ⁺ : calculated mass: 416.1910, measured mass: 416.1897

Example 6

5 '- (4- (hexyl) - [1,2,3] triazol-1-yl) -5', 2'-dideoxythymidine

In a flask, 200 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.75 mmol) and 82.65 mg of non-1-yne (1 equivalent) in solution 0 are introduced. 1 M in a THF water mixture (1/1). 30 mg of sodium ascorbate (0.2 equivalent, 0.15 mmol) and 12 mg of copper sulfate (0.1 equivalent, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 8/2). 130 mg of a white solid are obtained.

RF: 0.62 (AcOEt / MeOH 8/2)

Yield: 46%

Example 7

5 '- (4- (heptyl) - [1,2,3] triazol-1-yl) -5', 2'-ideoxythymidine

In a flask, 200 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.75 mmol) and 93 mg of non-1-yne (1 equivalent) in 0.1 M solution are introduced into a flask. in a THF water mixture (1/1). 30 mg of sodium ascorbate (0.2 equivalent, 0.15 mmol) and 12 mg of copper sulfate (0.1 equivalent, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 85/15). 120 mg of a white solid are obtained.

RF: (AcOEt / MeOH 85/15)

Yield: 41% ¹ H NMR (300.13 MHz, CDCl ₃ ): δ 0.83 (t, y = 6 Hz, 3H, CH ₃ ), δ 1, 25

(m, 8H, CH ₂ ), δ 1, 55 (m, 2H, CH ₂ ), δ 1, 79 (s, 3H, CH ₃ ), δ 2.10 (t, / = 6 Hz, 2H,

CH ₂ ), δ 2.61 (t,; = 6 Hz, 2H, CH ₂ ), δ 4.06 (s, 1H, CH) ,. δ 4.27 (s, 1H, CH), δ 4.59 (m, 2H, CH ₂ ), δ 5.5 (s, 1H, OH), δ 6.16 (t, j = 6 Hz , 1H, CH) ,. δ 7.29 (s, 1H, CH), δ 7.82 (s, 1H, CH), δ 11, 31 (s, 1H, NH).

¹³ C NMR (75.47 MHz, DMSO d ₆ ): δ 12.6 (CH ₃ ), δ 14.4 (CH ₃ ), δ 22.5 (CH ₂ ), δ 25.4 (CH ₂ ), δ 28.9 (CH ₂ ), δ 29.0 (CH ₂ ), δ 29.4 (CH ₂ ) ,. δ 31, 7 (CH ₂ ), δ 38.4 (CH ₂ ), δ 51, 5 (CH ₂ ), δ 71, 1 (CH), δ 84.4 (CH), δ 110 (C), δ 123.1 (CH), δ 136.5 (CH), δ 147.4 (C), δ 150.9 (C = O), δ 164.1 (C = O).

Example 8

5 '- (4- (2,2-ditridecyl- [1,3] dioxolan-4-ylmethoxymethyl) - [1,2,3] triazol-1-yl) -5', 2'-ideoxythymidine

264 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (1 mmol) and 500 mg of 4-Prop-2-ynyloxymethyl-2,2-ditridecyl- [1, are introduced into a flask, 3] dioxolane (1 equivalent) in 0.1 M solution in THF water (1/1). 39.5 mg of sodium ascorbate (0.2 equivalents, 0.2 mmol) and 16 mg of copper sulfate (0.1 equivalents, 0.1 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is then immediately adsorbed on silica and the solvent removed by evaporation. The compound is obtained pure by column chromatography (AcEt / MeOH 8/2). 550 mg of a white solid are obtained. Yield: 72%

MS High resolution [M + H] ⁺ : calculated mass: 774.5745, measured mass: 774.5739

Example 9

5 '- (4- (2,2-ditridecyl- [1,3] dioxolan-4-ylbutoxymethyl) - [1,2,3] triazol-1-yl) -5', 2'-idoxythymidine

195 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.73 mmol) and 400 mg of 4- (4-Prop-2-ynyloxy-butyl) -2 are introduced into a flask. 2-ditridecyl- [1, 3] dioxolane (1 equivalent) in 0.1M solution in a THF water (1/1) mixture. 30 mg of sodium ascorbate (0.2 equivalents, 0.15 mmol) and 12 mg of copper sulfate (0.1 equivalent, 0.073 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 9/1). 180 mg of a white solid are obtained.

RF: 0.43 (AcOEt / MeOH 9/1)

Yield: 30% Example 10

5 '- (4 - ((O-cholesteryl) methyl) - [1,2,3] triazol-1-yl) - 5', 2'-ideoxythymidine

In a flask, 170 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.63 mmol) and 270 mg of o-propargylcholesterol as described in Preparation 7 (1 equivalent) are introduced. 0.1 M solution in a THF water mixture (1/1). We add, successively:

20 mg of sodium ascorbate (0.2 equivalent, 0.13 mmol) and 10 mg of copper sulfate (0.1 equivalent, 0.063 mmol). The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography

(AcOEt / MeOH 8/2). 260 mg of a white solid are obtained.

RF: 0.57 (AcOEt / MeOH 8/2)

Yield: 59% MS [M + H] ⁺ : 692.3

Example 11 1 _l 12-bis- [5 ^l - (4- (méthylH1 _l 2 _I 3] triazol-1-yl) ^-5> _l 2 ^I didéoxythymidine] - oxydodécane

In a flask, 100 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.375 mmol) and 52 mg of 1,12-dipropargyloxydodecane prepared from the compound described in Preparation 6 (0 , Equivalent) in 0.1M solution in a water THF (1/1) mixture. 15 mg of sodium ascorbate (0.2 equivalents, 0.075 mmol) and 6 mg of copper sulfate (0.1 equivalents, 0.0375 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 8/2). 90 mg of a white solid are obtained.

Yield: 59%

¹ H NMR (300.13 MHz, MeOH d ₄ ): δ 1, 28 (m, 16H, CH ₂ ), δ 0.83

(m, 4H, CH ₂ ), δ 1, 89 (s, 6H, CH ₃ ), δ 2,17 (s, 2H, CH ₂ ), δ 2.25 (m, 4H ₁ CH ₂ ), δ 3 , 51 (t, y = 6 Hz ₁ 4H, CH ₂ ), δ 4.18 (m, 2H, CH) δ 4.42 (m, 2H ₁ OH) δ 4.58 (s, 4H,

CH ₂ ), δ 4.76 (qd, y = 6 Hz, 4H, CH ₂ ), δ 6.21 (t,) = 6 Hz, 2H ₁ CH) ₁ δ 7.23 (s, 2H,

CH), δ 7.99 (s, 2H ₁ CH). Example 12 ^5> - (4- (1 (/; - hydroxy-hexyl) - [1, 2 _I 3] triazol-1-yl) -5 ^l, 2 ^l didéoxythymidinθ

215 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.8 mmol) and 101.5 mg of (R) oct-1-yn-3-ol are introduced into a flask ( 1 equivalent) in 0.1 M solution in a THF water (1/1) mixture. 31.5 mg of sodium ascorbate (0.2 equivalents, 0.15 mmol) and 13 mg of copper sulfate (0.1 equivalent, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is then immediately adsorbed on silica and the solvent removed by evaporation. The compound is obtained pure by column chromatography (AcEt / MeOH 9/1). 240 mg of a white solid are obtained.

RF: 0.48 (AcEt / MeOH 9/1)

Yield: 76%

Example 13

5 '- (4- (1 (S, -hydroxyhexyl) - [1,2,3] triazol-1-yl) -5', 2'-ideoxythymidine

215 mg of δ'-azido-δ'-deoxythymidine as described in Preparation 3 (0.8 mmol) and 101.5 mg of (S) oct-1-yn-3-ol are introduced into a flask ( 1 equivalent) in 0.1 M solution in a THF water (1/1) mixture. 31.5 mg of sodium ascorbate (0.2 equivalents, 0.15 mmol) and 13 mg of copper sulfate (0.1 equivalents, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is then immediately adsorbed on silica and the solvent removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 85/15). 255 mg of a white solid are obtained.

RF: 0.48 (AcOEt / MeOH 85/15)

Yield: 78%

Example 14

5 '- (4- (1-hydroxyhexyl) - [1,2,3] triazol-1-yl) -5', 2'-ideoxyadenosine

In a flask, 200 mg of 5'-azido-5'-deoxythymidine as described in Preparation 3 (0.75 mmol) and 95 mg of the racemic mixture of oct-1-yn-3-ol (1 equivalent) in 0.1M solution in a mixture

THF water (1/1). 30 mg of sodium ascorbate (0.2 equivalent, 0.15 mmol) and 12 mg of copper sulfate (0.1 equivalent, 0.075 mmol) are added successively. The reaction medium is stirred and heated at 60 ^° C. for 5 h. The mixture is then cooled to room temperature. The reaction medium is immediately adsorbed on silica and the solvent is removed by evaporation. The compound is obtained pure by column chromatography (AcOEt / MeOH 8/2). 240 mg of a white solid are obtained.

RF: 0.47 (AcOEt / MeOH 8/2) Yield: 80%

High resolution MS [M + H] ^+: mass calculated: 576.4125, measured mass: 576.4120

EXAMPLE 15 Preparation of the Nanoparticles The 3 '- (1,2-dipalmitoyl-sn-glycero-3-phosphate) thymidine compound (di C16 dT) prepared in Example 2 and as the compound of formula (I) is used as the compound of formula (I). lipid dioleylphosphatidylcholine (DOPC).

1) Preparation of stock solutions

a) Preparation of the cis-platinum solution:

15 mg of cis-platinum are solubilized in 10 ml of milliQ water (5 mM). This suspension is stirred for 1 min (vortex), and then incubated at 37 ^° C. for 24 h.

b) Preparation of lipid solutions

Solution A: 20 mg of diC16dT are solubilized in 2 mL of chloroform (10 mg / mL). This sample is stored at -20 ^° C. Solution B: DOPC: 20 mg / mL solution in chloroform, stored at -20 ° C. 2) Preparation of lipid formulations

In an eppendorf tube ^® 2 ml_, 52.3 μl_ of solution A are mixed with 23.6 μl_ of B. These volumes correspond to a ratio of 1/1 by mol. The chloroform is evaporated under nitrogen so as to obtain a homogeneous lipid film.

3) Preparation of nanoparticles

1.2 ml of the cis-platinum solution pre-incubated at 37 ° C are used to rehydrate the previously prepared lipid film. The mixture is incubated at 37 ° C for 30 min. A series of 10 cycles of heating (water bath at 45 ° C) and freezing (dry ice / methanol -78 ° C) is carried out.

4) Washing and recovery of nanoparticles Once the series of 10 cycles has been completed, the tube is centrifuged at

2100 rpm at 4 ⁰ C for 5 min. After removal of the supernatant, the pellet is resuspended in 1 ml of milliQ water. A second centrifugation is performed (2100 rpm at 4 ° C for 5 min), then the supernatant is removed and the pellet is dried. The concentration (ICP / Optical) of the resuspended pellet in 1 mL of milliQ water is 2.844 mM equivalent in cisplatin (852.2 mg / L). This concentration corresponds to 47.4% of the cisplatin initially used.

EXAMPLE 16 Preparation of Nanocapsules The compound of formula (I) used is the thymidine compound

3 '- (1,2-dipalmitoyl-sn-glycero-3-phosphate) (di C16 dT) prepared in Example 2 and as co-lipid dioleylphosphatidylcholine (DOPC).

1) Preparation of stock solutions - a) Preparation of the cis-platinum solution: 15 mg of cis-platinum are solubilized in 10 ml of milliQ water (5 mM). This suspension is stirred for 1 min (vortex), and then incubated at 37 ^° C. for 24 h, with occasional stirring.

b) Preparation of lipid solutions: Solution A: 20 mg of diC16dT are solubilized in 2 ml of dichloromethane (10 mg / ml). The solution is stored at -2O ⁰ C.

Solution B: DOPC: 20 mg / mL solution in dichloromethane, stored at -20 ^° C.

2) Preparation of lipid formulations

In an eppendorf tube ^® 2 mL, 52.3 .mu.l of solution A are mixed with 47,2μL of B. These volumes correspond to a ratio of 1/1 by mol.

The dichloromethane is evaporated with compressed nitrogen so as to obtain a homogeneous lipid film.

3) Preparation of nanoparticles

1.2 ml of the cis-platinum solution (5 mM) are incubated overnight at room temperature with the previously prepared lipid film, without stirring. A series of 10 cycles of heating (water bath at 45 ⁰ C) and freezing (dry ice / ethanol -78 ° C) is carried out.

4) Washing and recovery of nanoparticles

After the 10-cycle run is complete, the suspension is stirred and placed in a glass hemolysis tube and sonicated for 5 minutes. After sonication, the suspension is centrifuged at

1000 rpm / 2.5 min / 20 ° C to remove the large capsules found in the pellet that will be eliminated. The supernatant is again centrifuged at

10000 rpm / 5min / 20 ° C. The nanoparticles are found in the pellet. The latter is resuspended in 1 ml of milliQ water and a second centrifugation is carried out. The pellet is suspended in 1 mL and dosed in

Inductively Coupled Plasma (ICP) -Optic. Example 17: stability test

The nanoparticles prepared according to the protocol of Example 16 are assayed in optical ICP (the measured value corresponds to the total concentration). The suspension of the nanoparticles is aliquoted in 5 eppendorf® tubes (150 μL). These are incubated at 37 ° C with shaking

(300 rpm) for different times (0, 2.5, 5, 10 and 24 hours).

At a given time (x), the tube is centrifuged at 14,000 rpm / 10min / 20 ° C and 50 μl of supernatant (recovered gently so as not to resuspend the pellet) are assayed.

Nanoparticles based on 1,2-dioleoyl-sn-glycero-3- [phospho-

L-serine] (DOPS) with 1,2-dioleoyl-sn-glyero-3-phosphocholine (DOPC) as colipid are prepared according to the same protocol for comparison. The percentage of cis-platinum release is calculated according to the following equation:

% cis-platinum released = Cx-CO / Ct-CO

Cx: concentration found at a given time (x).

CO: concentration found in the supernatant before incubation. Ct: total concentration found without incubation and without centrifugation.

The cisplatin release curve as a function of the incubation time shown in FIG. The nanoparticles of Example 16 are represented by the symbol -O- and the nanoparticles based on

The results show that the half-life time (incubation time required to release 50% of cis-platinum) is greater than 24 hours for the nanoparticles according to the invention, whereas it is of the order of 6.5 h for nanoparticles based on DOPC / DOPS.

Example 18: Measuring Nanoparticle Size

The nanoparticles prepared according to the protocol of Example 16 were analyzed with a MALVERN zeta-stabilizer. The nanoparticles are suspended in 2 ml of milliQ water (volume necessary for size measurement). The concentration is about 0.5 mM (the suspension must be turbid to diffuse the light). Single-use vats (1 cm / 1 cm) are used for the measurement.

The results show that more than 95% of the nanoparticles have a size between 100 and 250 nm with a polydispersity of 0.228.

Example 19: Intracellular cisplatin dosage

Protocol

IGROV1 cells (ovarian adenocarcinoma line) at 80% confluency (10 cm diameter dish) are treated with 100 μM of free cisplatin or encapsulated in the nanoparticles of Example 16 for 2, 4 or 6 hours. . At the end of this treatment, two washes with PBS are carried out. The cells are treated with trypsin and resuspended in PBS. Two PBS washes of cell suspensions were performed (centrifugation 1000 rpm / 1 min). The cells are suspended in 1 mL of PBS and counted.

ICP-optical assay

10 ⁶ cells are lysed with 500 μl of the cell lysis solution (lysis buffer from SIGMA). The volume is supplemented with milliQ water at 1% HNO ₃ acid to reach 5 mL.

Results

The results are shown in FIG. 2, which shows the concentration of cis-platinum released after cell lysis as a function of time, corresponding to the concentration of internalized cis-platinum in the treated cells.

For each time, the hatched column (left) corresponds to free cis-platinum and the dotted column (right) to nanoparticles containing cis-platinum. The results show that the internalisation of cis-platinum is significantly more efficient in the presence of nanoparticles. For example, under identical conditions (10 ⁶ cells, 100 μM, 2 h) 0.5 nanomole of cis-platinum is internalized in the case of free cis-platinum whereas internalisation is 4.5 times greater in the case of free cisplatin. case of nanoparticles (2.3 nanomoles).

EXAMPLE 20 Study of the Cytotoxic Effects of the Nanoparticles Prepared According to the Invention The nanoparticles were prepared according to the process described in Example 15. The compound C20dT of formula

in which n = 18, described in Nathalie Campins et al., New J. Chem., 2007, 31,

1928-1934).

Protocol

The test used uses the human cancer cell line HCT8 (colorectal adenocarcinoma), known for its intrinsic resistance to platinum derivatives.

The protocol is as follows:

At D-3, the cells are implanted in 96-well plates at the density of 50,000 cells per well. At 0, the cells are treated with the test formulation, either for a short exposure time (30 min) in physiological saline or for a long exposure time (72 h) in culture medium. The range of concentrations achieved includes the points 0 - 0,4 - 0,8 - 1, 5 - 3 - 6,25 -

12.5 - 25 - 50 and 100 mg / L Negative controls (untreated cells) and positive controls (cisplatin) were performed simultaneously.

- At D3, the culture medium is changed, and the treatment of 72 hours stopped.

- At J6, the protocol is finished, and the cells remaining at the bottom of the wells are stained with crystal violet.

Expression of results

The survival of the cells was determined, and the percentage of overall death (or cytotoxicity) obtained at the different concentrations of the test formulation was compared with that obtained with the negative controls (untreated cells). The cytotoxicity results were presented in the form of dose-effect curves characterized by their inhibitory concentration (IC ₅₀ ), that is to say the concentration at which 50% of dead cells are observed.

Preliminary results (Clsn) at 30 minutes

The results are reported in Table 1 below.

Table 1

The results show that the nanoparticles according to the invention, containing the compound of formula (I) C20dT present, in this test, a 30-min cytotoxicity expressed by Cl ₅₀ at a significantly lower dose than cis-platinum alone.

Example 21 Study of the Cytotoxic Effects of the Nanoparticles Prepared According to the Invention

The compound of formula (I) used was:

diC16dT (Thymidine 3 '- (1, 2-dipalmitoyl-s /? - glycero-3-phosphate) of Example 2 and a colipid (DOPC), or

5 '- (4- (1 (N-hydroxy-hexyl) - [1,2,3] triazol-1-yl) -5', 2'-ideoxythymidine of Example 12, but without add colipid.

The nanoparticles were prepared according to the method described in Example 15, but with a single heating / cooling cycle for the compound of Example 12.

Protocol

1000 to 5000 IGROV1 cells are incubated in 100 μl of medium with serum per well (96-well plate). After 24 hours the medium is removed and the cells are treated for 1 to 3 days with the formulations according to the invention and / or the free cis-Pt (at the desired concentrations). The cells are incubated at 37 ° C. in 200 μl of medium with serum. The cell viability is revealed in colorimetry by an MTS test at the end of the treatment.

Expression of results

The survival of the cells was determined, and the percentage of overall death (or cytotoxicity) obtained at the different concentrations of tested formulations was compared with that obtained with the negative controls (untreated cells). The cytotoxicity results were presented in the form of dose-effect curves characterized by their inhibitory concentration (IC 50), that is, the concentration at which 50% of dead cells are observed. The results are reported in Table 2 below, in which the IC 50 is expressed either in μM or in mg / L cis-platinum (incubation time: 24h). Table 2

The results show that the nanoparticles according to the invention, containing the compounds of formula (I), prepared in the presence or absence of colipid, exhibit in this test a cytotoxicity at 24 h expressed by IC ₅₀ at a dose significantly lower than that cis-platinum alone.

EXAMPLE 22 Study of the Cytotoxic Effects of the Nanoparticles Prepared According to the Invention

a / Preparation and treatment of the cells:

In a 96-well plate, 2500 cells (IGROV1, SKOV3, ovarian adenocarcinoma lines) per well are incubated in 100 μl of the medium with serum. After 24 hours, the medium is aspirated and the cells are treated with free cis-platinum or encapsulated in the nanoparticles of Example 16 in 100 μL of medium without serum at different concentrations (500, 100, 10, 1, 0.1, 0.01 0.001 μM). After 24 hours of treatment, the medium is removed and the cells are washed twice with 100 μl of PBS and then incubated with 100 μl of medium with serum.

b / Revelation of toxicity:

48 hours after the two washes, cell viability is revealed by adding 20 μL of MTS. The absorbance at 490 nm is measured after 2 to 4 incubation hours at 37 ° C. Absorbance is proportional to cell viability.

c / results The results are shown in Figure 3, which shows the concentration required to obtain 50% cell death (IC50) with free cis-platinum (column A) or nanoparticles containing cisplatin (column B).

Figure 3A relates to the IGROV1 cell line and Figure 3B relates to the SKOV3 cell line.

The results show the nanoparticles of Example 16 containing cis-platinum are more effective than free cisplatin in both cell lines, IGROV1 (sensitive to cisplatin) and SKOV3 (cisplatin-resistant). On the IGROV1 line, we obtain 50% of cell death with

0.27 μM of nanoparticles containing cis-platinum whereas 2.41 μM of free cisplatin must be used to obtain this result. On the SKOV3 line, 50% of cell death is obtained with 0.54 μM of nanoparticles containing cis-platinum against 4.3 μM of free cis-platinum. The nanoparticles containing cis-platinum are respectively 9 and 8 times more effective than free cisplatin on IGROV1 and SKOV3 lines.

Claims

A method of encapsulating a therapeutic agent comprising the steps of: a) preparing a mixture of at least one functional amphiphilic compound of formula (I)

in which

X represents an oxygen atom, sulfur atom or a methylene group,

B represents a purine or pyrimidine base such as uracil, adenine, guanine, cytosine, thymine, hypoxanthine, or their derivatives, or a non-natural mono- or bi-cyclic heterocyclic base of which each ring has 4 to 7 ring members, optionally substituted;

L ₁ and L ₂ , which may be identical or different, represent hydrogen, an oxycarbonyl group -O-C (O) -, a thiocarbamate group -O-C (S) -NH-, a carbonate group -O-C (O) ) -O-, a carbamate group -O-C (O) -NH-, an oxygen atom, a phosphate group, a phosphonate group or a heteroaryl group comprising 1 to 4 nitrogen atoms, substituted or unsubstituted by a hydrocarbon chain, saturated or unsaturated, linear or branched C ₂ -

C30. or else L ₁ and L ₂ , together, form a ketal group of formula

or else Li or L ₂ represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, not substituted or substituted with a linear or branched C ₂ -C ₃ o alkyl chain _; Ri and R ₂ , identical or different, represent

a linear or branched C ₂ -C ₃₀ , preferably C ₆ -C ₂ S, in particular C ₈ -C 25, saturated or partially unsaturated hydrocarbon-based chain, optionally totally or partially fluorinated, unsubstituted or substituted on the carbon of chain end with a fluorine atom or with a benzyl or naphthyl ester or ether, or

a diacyl chain in which each C ₂ -C ₃ acyl chain, or

a diacylglycerol, sphingosine or ceramide group, or when Li or L ₂ represents hydrogen and the other represents a hydroxyl group or a heteroaryl group comprising 1 to 4 nitrogen atoms, Ri and R ₂ do not exist ;

R ₃ represents a hydroxy, amino, phosphate, phosphonate, phosphatidylcholine, O-alkylphosphatidylcholine, thiophosphate, phosphonium, NH ₂ -R ₄ , NHR ₄ R ₅ or NR ₄ RsR _{6 group} in which R ₄ , R 5 and Rβ, which are identical or different, represent a hydrogen atom or a linear or branched C ₁ -C ₅ alkyl or hydroxyalkyl chain, or

a linear or branched C ₂ -C ₃ ₀ alkyl chain optionally substituted by a hydroxyl group, or a cyclodextrin residue, or

- a remainder

R ₇

H - (- CH ₂ -C-) _{n -} HI

CO-V- wherein V is -O-, -S-, or -NH-, R ₇ is H or

CH ₃ , and n = 1 to 500, or

a group - (CH ₂ VV-Re, in which R ₈ represents a C ₂ -C ₃ O alkyl, and n = 1 to 500, or

a heteroaryl group containing 1 to 4 nitrogen atoms, unsubstituted or substituted by a C2-C30 alkyl, or by a (CH ₂ ) _m -O- (CH ₂ ) _p -R _{9 group} in which m = 1 at 6 and p = 0 to 10 and R ₉ represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C2-C ₃₀ alkyl or a sterol residue, or

- R ₃ is covalently bonded to another substituent R ₃ , identical or different, of another compound of formula (I), identical or different, to form a compound of formula (I) in dimer form, and

a therapeutic agent, preferably an anti-tumor agent, b) subjecting said mixture to repeated cycles of heating and freezing, so as to obtain nanoparticles containing said therapeutic agent, and c) recovering the nanoparticles containing said therapeutic agent thus obtained .

2. Method according to claim 1, characterized in that, in the formula (I), X represents oxygen.

3. Method according to one of claims 1 or 2, characterized in that, in formula (I), B represents thymine or adenine.

4. Method according to any one of claims 1 to 3, characterized in that, in formula (I):

X and B are as defined in any one of claims 1 to 3; Li represents a phosphate group, L ₂ represents hydrogen, R 1 represents a C ₂ -C ₃₀ alkyl group or a diacyl group in which each acyl chain is C ₂ -C ₃ _O and R ₃ is a hydroxyl group; or

L ₁ and L ₂ represent an oxygen atom, R 1 and R ₂ represent hydrogen and R ₃ represents a triazole, tetrazole, pyrazole or imidazole group substituted with a C ₂ -C ₃₀ alkyl group, or

Li represents a triazole, tetrazole, pyrazole or imidazole group, L ₂ represents hydrogen, R 1 represents a C ₂ -C ₃₀ alkyl group, and R _{3 represents} a hydroxy group, or

Li represents a hydroxy group, L ₂ represents hydrogen and R ₃ is a triazole group substituted by a C ₂ -C ₃ O alkyl chain, optionally substituted by a hydroxyl group, or R ₃ is a group or a group - (CH ₂ ) nVR ₈ , wherein V is -O- or -NH- and R a is C 2 -C 30 alkyl, or

- 1 represents a hydroxy group, L2 represents hydrogen and R3 is a triazole group substituted by a (CH ₂ ) mO- (CH ₂ ) _p -R _{9 group} in which m = 1 to 6 and p = 0 to 10 and Rg represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C2-C ₃₀ alkyl group or with a sterol residue, or

Li represents a hydroxy group, L ₂ represents hydrogen and R ₃ is a triazole group substituted by a (CH 2) _m -O- (CH ₂ ) _p -R 9 group in which m = 1 to 6 and p = 0 to Covalently bonded to another identical R 3 substituent of another compound of formula (I), identical to form a compound of formula (I) as a dimer, or

Li represents a phosphate group, ₁ represents hydrogen, R ₁ represents a diacyl chain in which each diacyl chain is C ₂ -C ₃₀ , and R 3 is a hydroxyl group.

5. Method according to any one of claims 1 to 3, characterized in that, in formula (I):

X, B, L ₂ , R 1 and R ₂ are as defined in formula (I), and

the substituent Li or the substituent R ₃ consists of or comprises an unsubstituted or substituted triazole group.

6. Method according to any one of claims 1 to 5, characterized in that it comprises the steps of:

- dissolving the compound of formula (I) in an organic solvent to form a lipid mixture, - evaporating said mixture to form a film,

solution of the desired quantity of therapeutic agent, preferably an anti-tumor agent in distilled water,

rehydrate the lipid film in the therapeutic agent solution, preferably an anti-tumor agent, subjecting the mixture thus obtained to a heating and cooling cycle carried out from 1 to 10 times.

7. Method according to any one of claims 1 to 6, characterized in that the compound of formula (I) is dissolved in an organic solvent in the presence of a colipid.

8. The method of claim 7, characterized in that the colipid is selected from dioleylphosphatidylcholine (DOPC) and dioleylphosphatidyluridinephosphatidylcholine (DOUPC).

9. Method according to any one of claims 1 to 8, characterized in that the therapeutic agent is selected from platinum complexes or ruthenium capable of binding to platinum complexes, or the inorganic complexes without platinum to base of ruthenium II or III, titanium, gallium, cobalt, iron or gold.

10. Method according to any one of claims 1 to 9, characterized in that the therapeutic agent is selected from cis-platinum, carboplatin, oxaliplatin, nedaplatin and lobaplatin.

11. Nanoparticles obtainable by the process according to any one of claims 1 to 10.

12. Solid nanoparticles, characterized in that they consist of a core rich in therapeutic agent, preferably an anti-tumor agent, surrounded by one or more lipid layers consisting of compound of formula (I),

in which - X represents an oxygen atom, sulfur atom or a methylene group,

B represents a purine or pyrimidine base such as uracil, adenine, guanine, cytosine, thymine, hypoxanthine, or their derivatives, or a non-natural mono- or bi-cyclic heterocyclic base of which each ring comprises 4 to 7 ring members, optionally substituted; Li and L ₂ , which may be identical or different, represent hydrogen, an oxycarbonyl group -O-C (O) -, a thiocarbamate group -O-C (S) -NH-, a carbonate group -O-C (O) -O-, a carbamate group -O-C (O) -NH-, an oxygen atom, a phosphate group, a phosphonate group or a heteroaryl group comprising 1 to 4 nitrogen atoms, substituted or unsubstituted by a saturated or unsaturated, linear or branched C ₂ -C ₃₀ hydrocarbon-based chain, or alternatively, L ₁ and L ₂ , together, form a ketal group of formula

or alternatively Li or L ₂ represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched C2-C30 alkyl chain; Ri and R ₂ , identical or different, represent

a linear or branched C ₂ -C 30, preferably C ₆ -C ₂₅ , especially C ₈ -C ₂₅ , saturated or partially unsaturated hydrocarbon-based chain, optionally totally or partially fluorinated, unsubstituted or substituted on the end carbon; of a chain with a fluorine atom or with a benzyl or naphthyl ester or ether, or

a diacyl chain in which each C ₂ -C ₃₀ acyl chain, or a diacylglycerol, sphingosine or ceramide group, or

when Li or L ₂ represents hydrogen and the other represents a hydroxyl group or a heteroaryl group comprising 1 to 4 nitrogen atoms, R 1 and R ₂ do not exist;

R ₃ represents a hydroxy, amino, phosphate, phosphonate, phosphatidylcholine, O-alkylphosphatidylcholine, thiophosphate, phosphonium, NH ₂ -R ₄ , NHR ₄ R ₅ or NR ₄ R ₅ R _{6 group} in which R ₄ , R ₅ and R ₆ , which may be identical or different, represent a hydrogen atom or a linear or branched C ₁ -C ₅ alkyl or hydroxyalkyl chain, or

a linear or branched C ₂ -C _{3 0} alkyl _chain optionally substituted with a hydroxyl group, or a cyclodextrin residue, or

- a remainder

R ₇

H - (- CH ₂ -C-VH

CO-V- wherein V represents a bond -O -, - S-, or -NH-, Rγ represents H or

CH ₃ , and n = 1 to 500, or

a group - (CH ₂ ) HV-Rs, in which R ₃ represents a C ₂ -C ₃₀ alkyl, and n = 1 to 500, or

a heteroaryl group containing 1 to 4 nitrogen atoms, unsubstituted or substituted by a C ₂ -C ₃₀ alkyl, or by a (CH ₂ ) mO- (CH ₂ ) _p -R _{9 group} in which m = 1 at 6 and p = 0 to 10 and Rg represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C ₂ -C ₃₀ alkyl or by a sterol residue, or

- R ₃ is covalently linked to another substituent R ₃ , identical or different, from another compound of formula (I), identical or different, to form a compound of formula (I) in dimer form, with or without co-lipid.

13. Compound of formula (I)

in which

X represents an oxygen or sulfur atom,

B represents a purine or pyrimidine base such as uracil, adenine, guanine, cytosine, thymine, hypoxanthine, or derivatives thereof, or a non-natural mono- or bi-cyclic heterocyclic base of which each cycle comprises 4 to 7-membered, optionally substituted; and

Li, L ₂ , Ri, R ₂ and R ₃ are chosen from one of the following definitions:

Li represents a phosphate group, ₁ represents hydrogen, R 1 represents a C ₂ -C ₃₀ alkyl group or a diacyl group in which each acyl chain is C ₂ -C ₃₀ , and R ₃ is a hydroxyl group; or

Li represents a hydroxy group, L ₂ represents hydrogen and R ₃ is a triazole group substituted with a C ₂ -C ₃₀ alkyl chain, optionally substituted by a hydroxyl group, or R ₃ is a group or a group CH ₂ ) nVR ₈ , wherein V is -O- or -NH- and R ₈ is C ₂ -C ₃₀ alkyl, or

Li represents a hydroxy group, L ₂ represents hydrogen and R ₃ is a triazole group substituted by a (CH ₂ ) mO- (CH ₂ ) _p -Rg group in which m = 1 to 6 and p = 0 to 10; and Rg represents a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C ₂ -C ₃₀ alkyl group or a sterol residue, or

Li represents a hydroxy group, L ₂ represents hydrogen and R ₃ is a triazole group substituted by a (CH ₂ ) _m -O- (CH ₂ ) _p -R _{9 group} in which m = 1 to 6 and p = 0 to 10 covalently linked to another substituent R ₃ , identical, of another compound of formula (I), identical, to form a compound of formula (I) in dimer form, or

Li represents a phosphate group, L ₂ represents hydrogen, R 1 represents a diacyl chain in which each diacyl chain is C ₂ -C ₃₀ , and R ₃ is a hydroxyl group.

14. Compound of formula (I) in which

X, B, L 2, R 1 and R ₂ are as defined in claim 1; Li or R3 consists of or comprises an unsubstituted or substituted triazole group.

15. Nanoparticle comprising a compound of formula (I) according to one of claims 13 or 14 and a therapeutic agent.

16. Nanoparticle according to claim 15, characterized in that the therapeutic agent is an anti-tumor agent.

17. Nanoparticle according to any one of claims 11, 12, 15 or 16, characterized in that the therapeutic agent is selected from cis-platinum, carboplatin, oxaliplatin, nedaplatin and lobaplatin.

18. Use of the nanoparticles according to any one of claims 11, 12, 15, 16 or 17 for the transport or vectorization of therapeutic agents, in particular antitumor agents.

19. Use of the nanoparticles according to any one of claims 11, 12, 15, 16 or 17, for the intracellular delivery of therapeutic agents, in particular anti-tumor agents.

20. Use of the nanoparticles according to any one of claims 11, 12, 15, 16 or 17, for the preparation of anti-tumor drugs.

21. Nanoparticles according to any one of claims 11, 12, 15, 16 or 17 for the treatment of tumor diseases.